Should national pharmacare apply a value based insurance design?

CMAJ

22 July 2019 - The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, called for universal, single-payer, public pharmacare in Canada.

Private and public drug benefit plans in Canada use numerous forms of out-of-pocket charges for covered prescription drugs. When applied indiscriminately, cost-sharing can reduce patient adherence to medications, even for important classes of drugs such as anti-diabetic mediations. Reduced medication adherence because of cost-sharing can negatively affect the health of vulnerable populations, 

The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, called for universal, single-payer, public pharmacare in Canada.

Pharmacare is shaping up to be a defining issue of the 2019 federal election.

Read CMAJ article

Michael Wonder

Posted by:

Michael Wonder